Early Detection Initiative for Pancreatic Cancer (EDI)

Overview

Información sobre este estudio

The Early Detection Initiative for pancreatic cancer is a multi-center randomized controlled trial to determine if algorithm-based screening in patients with new onset hyperglycemia and diabetes can result in earlier detection of pancreatic ductal adenocarcinoma.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

- Patient must have given institutional consent for minimal risk studies.

- Patient must be ≥50 and ≤85 years of age at the time of diagnosis [index date
Parameters of Diabetes Mellitus (PDM)].

- Patient must have index weight and left-window weight values available in electronic
medical record (EMR).

- Patient must have hyperglycemia and/or diabetes as one of the following ≤90 days prior
to randomization (all glycemic parameters, except for HbA1c, must be measured in an
outpatient setting):

A. Glycated hemoglobin (HbA1c) ≥ 6.5%

OR

B. Any (2) PDMs on consecutive (≤90 days between PDMs) or simultaneous testing:

- Fasting Blood Glucose (FBG) ≥126 mg/dl

- Glycated hemoglobin (HbA1c) ≥ 6.5%

- Random Blood Glucose (RBG) ≥200 mg/dl

- 2 hour Post Glucose (PG) ≥ 200mg (11.1 mmol/L) during oral glucose tolerance test
(OGTT)

OR

C. Any one (1) PDM present followed by an anti- diabetes medication ≤90 days after the
index PDM date

- Patient must have ≥1 glycemic parameter measured in the past 91-548 days prior to the
index PDM date (Left Window) without meeting inclusion criteria A, B, or C.

Exclusion Criteria:

- Patient has declined institutional consent for minimal risk studies.

- Patient must not have any known past history of hyperglycemia and/or diabetes as
defined by inclusion criteria A, B, or C

*Transient diabetes (e.g. gestational and steroid-induced) is not an exclusion.

- Patient must not be on active treatment for cancer, carry a current diagnosis of any
cancer, and/or investigated for suspicion of recurrence of past cancer (except
non-melanoma skin cancer or carcinoma in-situ of the cervix).

*Ongoing work up for suspicion of pancreatic cancer is not an exclusion.

- Patient must not have had a definitive diagnosis of pancreatic cancer prior to index
PDM date.

- Patient must not be on any anti-diabetes medications prior to index PDM date.

- Patient must not be on chronic or acute use of steroid medications ≤90 days prior to
the index PDM date.

*Allowed: Nasal, topical steroids, oral budesonide, ophthalmic

- Patient must not have had an intra-articular steroid injection ≤ 7 days prior to the
index PDM date.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Shounak Majumder, M.D.

Comunícate con nosotros para obtener el estatus más reciente

Contact information:

Heather Streich

(507) 266-3778

Streich.Heather@mayo.edu

More information

Publicaciones

  • Patients with new-onset diabetes are known to be at a higher risk of developing pancreatic cancer. The Enriching New-Onset Diabetes for Pancreatic Cancer (ENDPAC) model was recently developed to identify new-onset diabetics with this higher risk. Further validation is needed before the ENDPAC model is implemented as part of a screening program to identify pancreatic cancer. Read More on PubMed
  • The risk of pancreatic cancer is elevated among people with new-onset diabetes (NOD). Based on Rochester Epidemiology Project Data, the Enriching New-Onset Diabetes for Pancreatic Cancer (END-PAC) model was developed and validated. Read More on PubMed
  • Of patients with new-onset diabetes (NOD; based on glycemic status) older than 50 years, approximately 1% are diagnosed with pancreatic cancer (PC) within 3 years. We aimed to develop and validate a model to determine risk of PC in patients with NOD. Read More on PubMed
  • It is unclear how long pancreatic ductal adenocarcinomas (PDACs) are present before diagnosis. Patients with PDAC usually develop hyperglycemia and diabetes before the tumor is identified. If early invasive PDACs are associated with hyperglycemia, the duration of hyperglycemia should associate with the time that they have had the tumor. Read More on PubMed
  • Although diabetes occurs frequently in pancreatic cancer, the value of new-onset diabetes as a marker of underlying pancreatic cancer is unknown. Read More on PubMed
.
CLS-20541819

Mayo Clinic Footer